April 3, 2024
CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations
BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical…
April 3, 2024
Washington D.C.’s 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (or the “Company”), a pharmaceutical company focused on developing…
April 3, 2024
Kemp Proteins and Columbia Biosciences Announce Strategic Partnership for Fluorophore Conjugation Solutions
April 2, 2024, Frederick, Maryland — Kemp Proteins LLC, a leading provider of monoclonal antibody development and gene-to-protein services, announced…
April 2, 2024
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April…
April 2, 2024
Major investments in Maryland’s life sciences sector
Investment in Maryland’s life sciences community is heating up only a few months into 2024. From new market launches to…
April 1, 2024
Maryland Life Science Trend Analysis 2024
Venture financing for Maryland’s life sciences industry in 2023 shows signs of recovery following the significant downturn in 2022, with…
April 1, 2024
Baltimore’s LaunchPort Welcomes New Resident JuneBrain
LaunchPort welcomes CEO Samantha Scott and her team as the latest Residents to join the Baltimore Peninsula site. JuneBrain Inc.…